You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab or Nivolumab in Patients with Advanced Solid TumorsPhase IB trial of rpt dose TRX518 singly and in combination
|
|---|---|
| Published in |
Clinical Cancer Research, May 2022
|
| DOI | 10.1158/1078-0432.ccr-22-0339 |
| Pubmed ID | |
| Authors |
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 53% |
| United Kingdom | 1 | 6% |
| Unknown | 7 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 76% |
| Scientists | 2 | 12% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 16% |
| Unspecified | 2 | 8% |
| Other | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Professor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 12 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Unspecified | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Agricultural and Biological Sciences | 2 | 8% |
| Other | 1 | 4% |
| Unknown | 12 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2022.
All research outputs
#3,167,002
of 25,340,976 outputs
Outputs from Clinical Cancer Research
#2,790
of 13,216 outputs
Outputs of similar age
#67,549
of 437,193 outputs
Outputs of similar age from Clinical Cancer Research
#49
of 127 outputs
Altmetric has tracked 25,340,976 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,216 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,193 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.